Clinical Trials Resource Center

Myasthenia Gravis (Chronic Weakness)

November 6, 2006

Aspreva reported negative preliminary results from a phase III trial of CellCept for the treatment of myasthenia gravis. This randomized, double-blind, placebo-controlled clinical trial enrolled subjects diagnosed with myasthenia gravis who received treatment for 36 weeks. Treatment was generally well tolerated, with the most commonly reported adverse events including diarrhea and muscle spasms. However, the trial failed to meet the primary endpoint of achieving minimal disease activity while maintaining designated low steroid and cholinesterase inhibitor doses. Based on the results, Aspreva plans to further analyze the data to determine a future course of action for the development of CellCept.

Related Medical Areas

This information does not represent a Lupus Research Institute endorsement of any listed study. It is merely a notice that the study is available. If you are presently under the care of a physician for lupus or other conditions, you should not disrupt your current program without discussing it with your doctor(s). Do not contact the Lupus Research Institute for information on these studies. Only contact the listed numbers. The Lupus Research Institute does not have any jurisdiction over or further involvement with these studies, other than to make people aware that they are being conducted.